GlassScriptPhysician profile
Kyle T Osborn
NPI 1417942582
$1,200.97
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $123 · 2021: $559.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $271.57 | 2019-2021 | |
| Novo Nordisk INC | $162.89 | 2019-2021 | |
| Amarin Pharma, INC. | $112.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.76 | 2019-2020 | |
| Astellas Pharma US INC | $85.54 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.05 | 2021 | |
| Sanofi Pasteur INC. | $49.68 | 2019 | |
| Glaxosmithkline, LLC. | $47.66 | 2019-2021 | |
| Abbvie INC. | $31.65 | 2021 | |
| Upsher-Smith Laboratories LLC | $24.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.65 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.52 | 2021 | |
| Eisai INC. | $18.27 | 2021 | |
| Merck Sharp & Dohme LLC | $16.63 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.28 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.23 | 2021 | |
| Lilly USA, LLC | $15.43 | 2021 | |
| Amgen INC. | $12.65 | 2019 | |
| Pfizer INC. | $12.22 | 2019 | |
| Allergan, INC. | $11.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.